Stanley Laman Group Ltd. grew its stake in Pfizer Inc. (NYSE:PFE) by 373.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 114,284 shares of the biopharmaceutical company’s stock after purchasing an additional 90,160 shares during the period. Stanley Laman Group Ltd.’s holdings in Pfizer were worth $3,839,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of PFE. Shine Investment Advisory Services Inc. acquired a new stake in shares of Pfizer in the 2nd quarter valued at approximately $102,000. D. Scott Neal Inc. boosted its position in Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the period. Herndon Capital Management LLC acquired a new stake in Pfizer during the 2nd quarter worth approximately $120,000. Franklin Parlapiano Turner & Welch LLC acquired a new stake in Pfizer during the 1st quarter worth approximately $121,000. Finally, Private Vista LLC boosted its position in Pfizer by 2,277.3% during the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 190,933 shares during the period. Institutional investors own 69.90% of the company’s stock.

Several equities research analysts recently commented on PFE shares. BMO Capital Markets set a $37.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, October 10th. ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Morgan Stanley upgraded shares of Pfizer from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $35.00 to $39.00 in a research report on Wednesday, September 20th. Finally, Deutsche Bank set a $38.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Two analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company. Pfizer currently has an average rating of “Buy” and an average target price of $38.66.

Shares of Pfizer Inc. (PFE) traded up $0.09 during midday trading on Friday, hitting $36.35. 18,584,405 shares of the stock were exchanged, compared to its average volume of 12,805,414. The firm has a market cap of $216,671.69, a P/E ratio of 14.54, a P/E/G ratio of 2.57 and a beta of 1.01. Pfizer Inc. has a 1 year low of $30.51 and a 1 year high of $36.78. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.61 EPS. sell-side analysts expect that Pfizer Inc. will post 2.59 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were given a $0.32 dividend. The ex-dividend date was Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.52%. Pfizer’s dividend payout ratio (DPR) is currently 79.01%.

In other news, EVP Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the sale, the executive vice president now owns 117,432 shares in the company, valued at approximately $4,186,450.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sally Susman sold 38,230 shares of Pfizer stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the sale, the insider now owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The disclosure for this sale can be found here. Insiders sold a total of 60,280 shares of company stock worth $2,118,988 in the last 90 days. Corporate insiders own 0.06% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Pfizer Inc. (PFE) Shares Bought by Stanley Laman Group Ltd.” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/12/03/pfizer-inc-pfe-shares-bought-by-stanley-laman-group-ltd.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.